Nektar Therapeutics (NKTR:NASDAQ) closed at $37.78 on November 10, 2026, down 0.12% on the day. The stock trades 65.3% below its 52-week high of $109.00 and 13.1% above its 52-week low of $33.40. Over the past year, it lost 34.8%. Nektar Therapeutics is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since November 10, 2025, NKTR closed higher on 122 days (48%). Its best day was February 10, 2026 (+51.07%) and its worst was October 1, 2026 (-22.39%). The stock moved 10% or more in a single session 8 times. It opened at least 5% above the previous day's high 2 times.
Nektar Therapeutics develops drug candidates based on its PEGylation and polymer conjugate technology platforms in the United States. Its product pipeline includes drug candidates in therapeutic areas comprising cancer, auto-immune disease, and chronic pain. The company offers MOVANTIK, an oral peripherally-acting opioid antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain; MOVENTIG for the treatment of opioid-induced constipation in adult patients who have an inadequate response to laxatives; and ADYNOVATE for use in treating Hemophilia A. Its drug candidates in clinical development stage comprises BAY41-6551, which is in Phase III clinical trial to treat gram-negative pneumonias; NKTR-214 that is in Phase 1/2 stage to treat cancer; NKTR-181 that is in Phase III clinical trial for treating chronic pain; and NKTR-358 to treat autoimmune diseases. The company's drug candidates in clinical development stage also include ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for metastatic breast cancer, as well as completed Phase II clinical trial stage for refractory ovarian cancer and second-line metastatic col...
Find more stocks like NKTR with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.